Outcome-Based Contracts for Pharmaceutical Products: Opportunities and Challenges
September 8, 2016
W Hotel, 515 15th Street NW, Washington, DC, 20004

Payers are expanding payment models that emphasize value over volume of services and are now starting to establish value-based arrangements for pharmaceuticals. In the past year, payers and pharmaceutical firms have announced outcome-based contracts for high cholesterol, heart failure and diabetes drugs. This roundtable will discuss the objectives, approaches and structures of recent value-based contracts. It will then discuss challenges to implementing these arrangements, potential solutions and the future outlook for value-based contracting for pharmaceuticals. The session will conclude with a special luncheon session on key issues and future directions for the FDA.

8:30 a.m. Coffee and Continental Breakfast
9:00 a.m. Welcome and Introduction
   Stuart Altman, Ph.D., Professor of National Health Policy, Brandeis University
9:15 a.m. Value-Based Contracting for Pharmaceuticals – Purchaser Perspective
   Chris Bradbury, Senior Vice President, Cigna Pharmacy Management
9:45 a.m. Discussion
10:30 a.m. Break
10:45 a.m. Value-Based Contracting for Pharmaceuticals – Pharmaceutical Firm Perspective
   Amy Rudolph, VP Health Economics and Outcomes Research, Novartis Pharmaceuticals
11:15 a.m. Discussion
12:00 p.m. Lunch
12:30 p.m. Accomplishments, Challenges and Future Directions for the FDA
   Margaret Hamburg MD, Former Commissioner, US Food and Drug Administration
2:00 p.m. Meeting adjourns